Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma.
- Author:
Hyo Jeong LEE
1
;
Hyo Jeong KANG
;
Kang Mo KIM
;
Eun Sil YU
;
Ki Hun KIM
;
Seung Mi KIM
;
Tae Won KIM
;
Ju Hyun SHIM
;
Young Suk LIM
;
Han Chu LEE
;
Young Hwa CHUNG
;
Yung Sang LEE
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Hepatocellular carcinoma; Fibroblast growth factor; Receptor; Immunohistochemistry; Survival
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Hepatocellular/metabolism/mortality/*pathology; Female; Hepatectomy; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms/metabolism/mortality/*pathology; Male; Middle Aged; Prognosis; Proportional Hazards Models; Protein Isoforms/metabolism; Receptors, Fibroblast Growth Factor/*metabolism; Young Adult
- From:Clinical and Molecular Hepatology 2015;21(1):60-70
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study was to determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) and neighboring nonneoplastic liver tissue, and elucidate its prognostic implications. METHODS: Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboring nonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patients who underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotype expression and overall survival was evaluated (development set). This association was also validated in 73 independent samples (validation set) by Western blot analysis. RESULTS: FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-year survival rate, 35.3% vs. 61.8%; P=0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgical prognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statistically significant in the validation set. CONCLUSIONS: FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival.
